Funk Douglas, Araujo Joseph, Slassi Malik, Lanthier James, Atkinson Jason, Feng Daniel, Lau Winnie, Lê Anh, Higgins Guy A
Campbell Family Research Institute, Centre for Addiction and Mental Health, Toronto M5S 2S1, Canada.
Transpharmation Ltd., Fergus N1M 2W8, Canada; Mindset Pharma, Toronto M5V 0R2, Canada.
Neuroscience. 2024 Feb 16;539:1-11. doi: 10.1016/j.neuroscience.2024.01.001. Epub 2024 Jan 4.
Psilocybin has received attention as a treatment for depression, stress disorders and drug and alcohol addiction. To help determine the mechanisms underlying its therapeutic effects, here we examined acute effects of a range of behaviourally relevant psilocybin doses (0.1-3 mg/kg SC) on regional expression of Fos, the protein product of the immediate early gene, c-fos in brain areas involved in stress, reward and motivation in male rats. We also determined the cellular phenotypes activated by psilocybin, in a co-labeling analysis with NeuN, a marker of mature neurons, or Olig1, a marker of oligodendrocytes. In adult male Sprague-Dawley rats, psilocybin increased Fos expression dose dependently in several brain regions, including the frontal cortex, nucleus accumbens, central and basolateral amygdala and locus coeruleus. These effects were most marked in the central amygdala. Double labeling experiments showed that Fos was expressed in both neurons and oligodendrocytes. These results extend previous research by determining Fos expression in multiple brain areas at a wider psilocybin dose range, and the cellular phenotypes expressing Fos. The data also highlight the amygdala, especially the central nucleus, a key brain region involved in emotional processing and learning and interconnected with other brain areas involved in stress, reward and addiction, as a potentially important locus for the therapeutic effects of psilocybin. Overall, the present findings suggest that the central amygdala may be an important site through which the initial brain activation induced by psilocybin is translated into neuroplastic changes, locally and in other regions that underlie its extended therapeutic effects.
裸盖菇素作为治疗抑郁症、应激障碍以及药物和酒精成瘾的方法已受到关注。为了帮助确定其治疗效果背后的机制,我们在此研究了一系列与行为相关的裸盖菇素剂量(0.1 - 3毫克/千克,皮下注射)对雄性大鼠应激、奖赏和动机相关脑区中即早基因c - fos的蛋白质产物Fos区域表达的急性影响。我们还通过与成熟神经元标志物NeuN或少突胶质细胞标志物Olig1进行共标记分析,确定了裸盖菇素激活的细胞表型。在成年雄性Sprague - Dawley大鼠中,裸盖菇素在包括额叶皮质、伏隔核、中央杏仁核和基底外侧杏仁核以及蓝斑在内的多个脑区剂量依赖性地增加Fos表达。这些影响在中央杏仁核最为明显。双重标记实验表明Fos在神经元和少突胶质细胞中均有表达。这些结果通过在更宽的裸盖菇素剂量范围内确定多个脑区的Fos表达以及表达Fos的细胞表型,扩展了先前的研究。数据还突出了杏仁核,尤其是中央核,这是一个参与情绪处理和学习且与参与应激、奖赏和成瘾的其他脑区相互连接的关键脑区,作为裸盖菇素治疗效果的潜在重要位点。总体而言,目前的研究结果表明,中央杏仁核可能是一个重要部位,通过它裸盖菇素诱导的初始脑激活可转化为神经可塑性变化,在局部以及构成其长期治疗效果基础的其他区域。